Ndife okondwa kulowa nawo atsogoleri amakampani ku CPHI South East Asia 2025, kuyambira pa Julayi 16 mpaka 18 ku MITEC ku Kuala Lumpur. Chochitikacho chimatenga malo opitilira 15,000 masikweya mita ndipo chikhala ndi owonetsa pafupifupi 400. Oposa akatswiri a 8,000 akuyembekezeka kupezekapo, limodzi ndi masemina ndi mabwalo a 60+ omwe amayang'ana kwambiri zomwe zikuchitika m'makampani, matekinoloje atsopano, ndi kayendetsedwe ka kayendetsedwe ka kayendetsedwe kake. Ndi mwayi wabwino kwambiri wolumikizana ndi maukonde ndi mgwirizano pamagulu onse ogulitsa mankhwala.

Za JYMed
 
JYMed ndi kampani yopanga mankhwala yomwe imayang'ana kwambiri pa peptide yomwe imachita kafukufuku, chitukuko, kupanga, ndi malonda. Timapereka ma CDMO ophatikizika kwathunthu ogwirizana ndi makasitomala amankhwala, zodzoladzola, ndi azanyama padziko lonse lapansi.

Mbiri yathu ikuphatikiza ma peptide API osiyanasiyana. Zogulitsa zamtundu wamtundu ngati Semaglutide ndi Tirzepatide zakwanitsa kumaliza zolemba za US FDA DMF.

Wothandizira wathu, Hubei JXBio, amayendetsa mizere yopangira peptide API yomangidwa kuti ikwaniritse miyezo ya cGMP kuchokera ku US FDA ndi NMPA yaku China. Malowa ali ndi mizere 10 yayikulu komanso yoyendetsa ndege ndipo imathandizidwa ndi ma protocol amphamvu a Quality Management System (QMS) ndi Environmental Health and Safety (EHS).

JXBio yadutsa kuwunika kwa GMP kuchokera ku US FDA ndi NMPA yaku China. Ndife onyadira kuzindikiridwa ndi othandizana nawo azamankhwala padziko lonse lapansi chifukwa chakuchita bwino kwambiri, chitetezo, komanso kutsata chilengedwe.

ZOPHUNZITSA ZABWINO

Lumikizanani nafe
Kwa mafunso, omasuka kulumikizana nafe:
● Global API & Cosmetic Inquiries:+ 86-150-1352-9272
● Kulembetsa kwa API & CDMO Services (US & EU):+ 86-158-1868-2250
● Imelo: jymed@jymedtech.com
● Adilesi:Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen, China.